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Nature versus Nurture in Glioblastoma
Microenvironment and Genetics Can Both Drive
Mesenchymal Transcriptional SignatureBrent A. Orr and Charles G. Eberhart
From the Johns Hopkins University School of Medicine,
Baltimore, Maryland
Glioblastomas (GBMs) are the most common malignant
brain tumors, but they are currently incurable. It is hoped
that targeted therapies may prove effective in improving
survival. Indeed, efforts to integrate multimodal molecular
and clinical data for brain tumors have begun to yield a
clearer picture of these aggressive neoplasms. The Cancer
Genome Atlas (TCGA)1 and the Repository of Molecular
Brain Neoplasia Data (REMBRANDT)2 both support numer-
ous data sets for mRNA and miRNA expression, DNA copy
number alterations, sequencing data, and both magnetic
resonance and histological images. Many of the molecular
underpinnings of GBM have been identified, themost abun-
dant mutations have been catalogued, and perturbed sig-
naling pathways have been elucidated.1 Mutations in isoci-
trate dehydrogenase 1 and 2 have been identified, and a
relationship to secondary GBM has been established.3,4 A
group of tumors with a CpG island methylator phenotype
has been described, portending an improved prognosis.5
These efforts and others have also resulted in the identifi-
cation of three or four transcriptional classes of GBM.4,6
Common to all of the major molecular classification
schemes for GBM is a group that characteristically shows
increased expression of mesenchymal genes. This mesen-
chymal expression signature has been associated with re-
duced survival and aggressive behavior.6
Despite these new insights into the biology of GBM,
and the promise of more tailored therapy on the horizon,
the diagnosis of GBM is still made using a more funda-
mental technique: microscopic examination of H&E-
stained slides. Over the years, several different histo-
pathological grading systems for GBM and other
astrocytomas have been used, including the Kernahan
system, the St. Anne/Mayo system, and the now current
World Health Organization (WHO) system.7,8 A consis-
tent feature of all these diagnostic schemata is the inclu-
1768sion of necrosis and vascular proliferation, two elements
of the tumor microenvironment, as indicators of poor
prognosis. The reduction in patient survival associated
with these features has withstood the test of time and
multiple confirmatory studies (reviewed by Brat et al9).
In this issue of The American Journal of Pathology, Coo-
per et al10 report their correlation of histopathological
features of the tumor microenvironment with gene ex-
pression patterns developed by the large multimodality
genomics efforts. They identify an intimate association
between necrosis in GBM and the mesenchymal tran-
scriptional class. The degree of necrosis demonstrated a
close association with genes that define mesenchymal
class, including master regulators such as STAT3 and
C/EBP-.11 Perhaps their most interesting finding was that
increasing mesenchymal expression signature among non-
mesenchymal-class tumors correlated with the extent of
necrosis (Figure 1). This highlights the important contribu-
tion of the tumor microenvironment in dictating mRNA tran-
scription and represents an important first step in integrat-
ing microscopic features and gene expression patterns in a
more quantitative and sophisticated way.
Correlating Morphological Analysis with
Large-Scale Genomics Data
The microscopic analysis of tumor morphology is not
new; in fact, it represents the basis of most studies in
anatomical pathology. Because of relatively recent tech-
nological advancements, however, quantitative mor-
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provements in imaging technology, including the ability
to scan slides and store images with relative speed,
increases in storage capacity, and production of power-
ful software platforms such as NIH Image and ImageJ
have facilitated robust quantitative analysis of histological
images on morphological grounds. Technology in molec-
ular biology allowing for multimodal data acquisition of
mRNA expression, genetics, and epigenetics has pro-
gressed even more rapidly. The field of glioma biology
benefited from GBM being selected early as one of the
tumors to be added to large public data sets such as the
TCGA, which include not only expression profiles but also
scanned slide and radiographic images for future corre-
lation with molecular data.
Computer-based image analysis has been used previ-
ously to evaluate the TCGA data set. For instance, Cooper
and colleagues12,13 earlier used nuclear segmentation
analysis to cluster TCGA tumors into three morphometric
classes. Similar to clustering by transcriptional classes,
which was reported by Verhaak et al,4 morphometric clus-
tering correlated with specific signaling pathways and sur-
vival profiles.12,13 An analogous approach, using distinct
criteria, generated five morphometric clusters from the
TCGA data set and was predictive of therapeutic out-
come.14 These early results are encouraging, but thus far
morphometric clustering has not shown the tight associa-
tion with specific molecular aberrations that has been ob-
served with transcriptional clustering.
The present contribution by Cooper et al10 differs from
previous efforts in that, rather than correlating intrinsic
features of single cells (most often nuclear details) with
TCGA data, they examined broader aspects of the tumor
microenvironment, evaluating three components: necro-
sis, angiogenesis, and macrophage infiltration. Necrosis
appeared to have the strongest relationship to the previ-
ously defined transcriptional classes, and in particular to
the mesenchymal subgroup.
Necrosis, Hypoxia, and Aggressiveness in GBM
Necrosis is a strong predictor of behavior in malignant
glioma.9 Intratumoral necrosis likely results from multiple
mechanisms. Focal necrosis occurs when the energy
requirements of the highly proliferative tumor cells out-
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Figure 1. Increased necrosis in GBM promotes a mesenchymal expression
signature.pace their own energy supply. However, a more complexmechanism has been suggested for large areas of ne-
crosis within GBM. These have been attributed to vascu-
lar thrombosis, which is often identified within tumors and
seen in a high proportion of pseudopalisades in GBM.15
Thrombosis of vessels may be related to a number of
derangements in the coagulation cascade, but has spe-
cifically been attributed to the induction of tissue factor by
tumor cells.16 Tissue factor may promote coagulation in
intratumoral vessels by directly inciting the coagulation
cascade.16 Finally, as antiangiogenic therapies such as
bevacizumab are increasingly used in malignant glio-
mas, we will likely encounter more therapeutically in-
duced hypoxia and necrosis.
How necrosis modulates gene expression is an area of
active investigation. It may involve the induction of hy-
poxia-inducible transcription factors (HIF1- and HIF2-
), the release of growth factors by dying cells, or eliciting
necrosis-associated inflammation. HIF transcription fac-
tors are concentrated around necrotic regions in GBM,
and they seem to promote a stem-like phenotype in tumor
cells.17,18 Li et al17 demonstrated that HIF2- was pref-
erentially expressed in brain tumor stem cells in response
to hypoxia, and knockdown of HIF2- inhibited in vitro
and in vivo tumorigenicity. Our research group found that
hypoxia increased the expression of stem cell markers
and increased the clonogenicity of GBM in a HIF1--
dependent manner.18 The findings reported by Cooper et
al10 thus suggest a broad link between necrosis, mesen-
chymal gene expression signature, stemness, and the
hypoxic response.
It would be worthwhile to determine whether HIF pro-
teins directly regulate the transcription of mesenchymal
genes in glioma. Definitive answers to that question will
require a chromatin immunoprecipitation approach, ei-
ther microarray (ChIP-chip) or high-throughput DNA se-
quencing (ChIP-seq); however, the available data sug-
gest that at least some mesenchymal genes are directly
regulated by HIF. For instance, the hexokinase genes
HEXA and HEXB are known targets of HIF1- (reviewed
by Keith et al19) and are among the genes that define the
mesenchymal transcriptional class.4 There is no known
association of the so-called master regulators of the mes-
enchymal class and HIF proteins in glioma; however,
C/EBP- has been shown to be a target of HIF2- outside
the brain.20 The present report provides some evidence
supporting the notion that C/EBP- could be regulated by
HIF in glioma as well. For instance, the authors demon-
strated that C/EBP- is expressed highly in the pseudop-
alisading perinecrotic cells in vivo, and is induced in hyp-
oxia in vitro.10 The staining of pseudopalisading glioma
cells around areas of necrosis has been reported previ-
ously for HIF1-.15 Other master regulators of the mes-
enchymal class, such as STAT3, may also modulate HIF
activity. For instance, it was recently reported that NF1
loss, a genetic change that clusters in the mesenchymal
transcriptional class, supports the activation of STAT3.21
STAT3 was shown in some carcinomas to form a tran-
scriptional complex with HIF1-, and loss of STAT3 at-
tenuated the ability of HIF1- to induce targets such as
VEGF.22,23 It would be interesting to determine whether
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glioma for such targets as C/EBP-.
Limitations
The work described by Cooper et al10 does have limita-
tions. For instance, although the relationship between
necrosis and the mesenchymal gene expression was
clear, other components of the microenvironment (such
as inflammatory infiltrates and angiogenesis) were exam-
ined less rigorously. This is largely due to limitations of
the available data set. In the case of angiogenesis, his-
topathological analysis of the stained sections yielded
only the descriptors ‘present’ and ‘absent’, precluding
meaningful subsequent correlations. The analysis of in-
flammatory infiltrates was similarly constrained. It has
been noted previously that the mesenchymal class con-
tains higher proportions of inflammatory cells,4 and in-
flammatory signatures were noted to be associated with
increased necrosis in the authors’ analysis of the data
set. Although Cooper et al10 did evaluate infiltration of
macrophages and their relationship to gene expression,
the authors relied on a categorical quantification for mac-
rophages (0, 1, and 2), rather than the more contin-
uous quantification (fractional area) used to quantify ne-
crosis. Furthermore, a systematic evaluation of other
nonmacrophage inflammatory cells was not performed,
because no specific markers were used. Thus, a contri-
bution of inflammatory cells or blood vessels to the mes-
enchymal transcriptional class has not really been ex-
cluded. Perhaps future additions to the TCGA will include
immunohistochemical analysis of vessels and inflamma-
tory cells, to allow for more robust evaluation of the tumor
microenvironment.
The Future
The present work raises several important questions cen-
tral to our understanding of glioma biology. For instance,
it will be critical to determine more precisely how genetic
alterations and the microenvironment interact within tran-
scriptional classes. It is clear that certain genetic altera-
tions cluster within specific transcriptional class, such as
IDH1 mutations in the proneural group and NF1 deletion
in the mesenchymal group.4 NF1 loss could directly reg-
ulate mesenchymal gene expression. Alternatively, NF1
loss could indirectly promote the mesenchymal transcrip-
tional class through a complex interaction with HIF sig-
naling, or by generating a hypoxic/necrotic tumor envi-
ronment through promotion of tumor overgrowth or
vascular thrombosis. Valuable information may also be
gleaned from the subsets of tumors that do not fit the
typical profiles, such as mesenchymal tumors with mini-
mal or no necrosis. It would be worthwhile to determine
whether other activators of cellular stress, such as inflam-
mation, can regulate the mesenchymal gene signature in
tumors with low or absent levels of necrosis.
Other more practical questions will have to be an-
swered as transcriptional classes become integrated into
clinical decision making. Cooper et al10 report that non-mesenchymal tumors become more mesenchymal with
increasing necrosis. This finding suggests a certain de-
gree of plasticity between transcriptional classes. It will
be important to determine if regional differences in tran-
scriptional class exist within individual tumors. If this oc-
curs to a significant degree, sampling in the hypoxic core
of a tumor may yield a mesenchymal signature, whereas
more peripheral sampling could yield an alternative tran-
scriptional class. Other clinical scenarios in which plas-
ticity within transcriptional class may prove important is in
the setting of tumor recurrence and after adjuvant ther-
apy. Although transcriptional class switching has not
been identified between the small subset of primary and
recurrent tumors previously analyzed,4 this finding will
need confirmation in larger data sets. The use of chemo-
therapy such as bevacizumab, which specifically inhibits
angiogenesis, may also drive a mesenchymal class by
increasing intratumoral hypoxia. The translation of molec-
ular advances into new therapeutic paradigms thus con-
tinues to grow more complicated.
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